EHJ Dialogue with Prof. Kazem Rahimi on blood pressure reduction 

Blood pressure reduction has been viewed as a key factor for reducing cardiovascular disease (CV) burden in hypertension. Recent analyses from the Blood Pressure Lowering Treatment Trialists’ (BPLTT) Collaboration have highlighted the beneficial effects of blood pressure lowering irrespective of blood pressure levels, age and CV risk profile, thus independently from a diagnosis of hypertension.
Does this challenge the concept of hypertension and characterizes BP reduction as a strategy of CV prevention, like for instance cholesterol reduction? To address these issues, Associate Editors Massimo Volpe and Carlo Patrono interview Prof. Rahimi, one of the leading authors and coordinator of the BPLTT Collaboration. Two top reviewers of the Journal and expert scientists in hypertension, Franz Messerli from Bern and Luis Ruilope from Madrid, will also join this Dialogue.
Recorded on 28 Apr 2022.